TERN in “GLP-1 Eats Everything”
Terns Pharmaceuticals
Terns is developing the oral GLP-1 candidate TERN-601, making it a direct small-cap play on more convenient obesity therapy.
TERN impact map — “GLP-1 Eats Everything”
How this story travels from the headline to TERN’s own business — positive, negative or mixed, direct or indirect, the mechanism, and how strong the exposure is.
Loading TERN impact map…
Price history, marked with story events
May 14, 2025 – May 15, 2026 · 251 sessions
Prices updated during market hours · refreshed about every 30 minutes while the market is open · delayed data, not for trading decisions
Numbered markers tie price moves to earnings, trial or study results, management comments and analyst or demand data. Loading events…
Full story
GLP-1 Eats Everything
Appetite suppression as a macro variable.
BULL side — Terns is developing the oral GLP-1 candidate TERN-601, making it a direct small-cap play on more convenient obesity therapy.
Read the full GLP-1 Eats Everything story